Gamal Esmat

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

Retrieved on: 
Thursday, May 9, 2019
Stem cells, Health, Biotechnology, Clinical trials, Pharmaceutical, Research, Science, Health, Medical specialties, Hepatology, Medicine, RTT, Clinical trial, Design of experiments, Drug discovery, Pharmaceutical industry, Cirrhosis, Hepatocellular carcinoma, Gamal Esmat

The multicenter, open-label PANASH study will evaluate the safety and preliminary efficacy of Prometheras investigational drug HepaStem, a novel allogenic cell-based therapy for severe liver diseases, in patients with cirrhotic and pre-cirrhotic NASH.

Key Points: 
  • The multicenter, open-label PANASH study will evaluate the safety and preliminary efficacy of Prometheras investigational drug HepaStem, a novel allogenic cell-based therapy for severe liver diseases, in patients with cirrhotic and pre-cirrhotic NASH.
  • The study will enroll a minimum of 24 patients via centers in 8 European countries.
  • Moving HepaStem into clinical studies in NASH in addition to the ongoing clinical evaluation in Acute-on-Chronic Liver Failure, represents a significant milestone for our therapeutic development activities.
  • Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation.

May Is Hepatitis Awareness Month: How Local Health Departments Protect Their Communities

Retrieved on: 
Tuesday, May 29, 2018
Medicine, Infectious causes of cancer, RTT, Immunology, Clinical medicine, Hepatitis, Viral hepatitis, National Association of County and City Health Officials, Gamal Esmat, Hepatitis B in China

The National Association of County and City Health Officials (NACCHO), representing the nation's nearly 3,000 local governmental health departments, supports local efforts to address hepatitis and advocates for increased funding to address the growth of hepatitis in the U.S.

Key Points: 
  • The National Association of County and City Health Officials (NACCHO), representing the nation's nearly 3,000 local governmental health departments, supports local efforts to address hepatitis and advocates for increased funding to address the growth of hepatitis in the U.S.
  • The most common types of hepatitis in the U.S. are hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV).
  • Without appropriate federal and state funding and public policies, local health departments will struggle to implement effective public health interventions to prevent and treat viral hepatitis.
  • The National Association of County and City Health Officials (NACCHO) represents the nation's nearly 3,000 local governmental health departments.